EQRx Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
EQRX Nasdaq 8731 https://www.eqrx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for EQRx Inc

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital - Aug 1st, 2023 11:00 am
EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results - May 8th, 2023 8:01 pm
EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023 - Apr 27th, 2023 12:00 pm
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress - Feb 23rd, 2023 12:00 pm
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2023 1:00 pm
EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer - Dec 19th, 2022 1:00 pm
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer - Dec 2nd, 2022 1:00 pm
EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results - Nov 10th, 2022 12:00 pm
EQRx to Participate in the Jefferies 2022 London Healthcare Conference - Nov 7th, 2022 1:00 pm
EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 - Oct 28th, 2022 12:00 pm